| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | ||
|---|---|---|---|---|---|---|
Revenue: | ||||||
Revenue | ||||||
488,543 | 64,867 | 43,401 | 0 | 0 | ||
Expenses: | ||||||
Cost of sales - intangible asset amortization | ||||||
5,690 | 2,713 | 0 | 0 | - | ||
Research and development | ||||||
292,852 | 130,340 | 126,890 | 68,459 | 50,885 | ||
Selling, general and administrative | ||||||
181,681 | 153,610 | 36,981 | 15,053 | 10,553 | ||
Total expenses | ||||||
450,469 | 295,683 | 163,871 | 83,512 | 61,438 | ||
(Loss) income from operations | ||||||
38,074 | -230,816 | -120,470 | -83,512 | -61,438 | ||
Other income (expense): | ||||||
Investment income | ||||||
5,505 | 5,631 | 1,813 | 295 | 16 | ||
Interest expense | ||||||
0 | 0 | 1,731 | 0 | 0 | ||
Other expense | ||||||
-615 | -189 | 104 | 0 | - | ||
Other income | ||||||
- | - | - | - | 0 | ||
(Loss) income before income tax expense | ||||||
42,964 | -225,374 | -120,284 | -83,217 | -61,422 | ||
Income tax benefit (expense) | ||||||
2,192 | 447 | 1,275 | 0 | 0 | ||
Net (loss) income | ||||||
40,772 | -225,821 | -121,559 | -83,217 | -61,422 | ||
Product [Member] | ||||||
Revenue | ||||||
42,253 | 2,237 | 0 | 0 | - | ||
Cost of sales | ||||||
4,569 | 1,820 | 0 | 0 | - | ||
Research and Development and License Revenue Under Collaborative Agreement [Member] | ||||||
Revenue | ||||||
436,118 | 50,630 | 43,401 | 0 | - | ||
Commercial Revenue [Member] | ||||||
Revenue | ||||||
- | - | - | 0 | - | ||
Licensing [Member] | ||||||
Revenue | ||||||
10,172 | 12,000 | 0 | 0 | - | ||
Cost of product/license | ||||||
5,400 | 7,200 | 0 | 0 | - | ||
Ionis [Member] | ||||||
Net loss share from commercial activities under arrangement with Ionis Pharmaceuticals, Inc. | ||||||
39,723 | 0 | 0 | - | - | ||
Preferred Stock [Member] | ||||||
Net income (loss) | ||||||
- | - | -28,385 | -83,217 | - | ||
Net loss per share, basic and diluted (in dollars per share) | ||||||
0.00 | 0.00 | -1.80 | -2.88 | - | ||
Weighted-average shares outstanding, basic and diluted (in shares) | ||||||
0 | 0 | 15,748 | 28,884 | - | ||
Net income (loss) per share of common stock, basic | ||||||
- | - | -1.80 | - | - | ||
Weighted-average shares of common stock outstanding, basic | ||||||
- | - | 15,748 | - | - | ||
Common Stock [Member] | ||||||
Net loss | ||||||
- | - | - | 0 | - | ||